Skip to content
value.today

Profectus Biosciences Inc.

Formerly Maryland Biotherapeutics Inc.

Total raised
$15 M
2 rounds on record
Latest round
$8 M
Jul 2009
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Profectus Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2009$8 MNo. 2$2 to $10 million

Profectus Biosciences Inc.: Raise no. 2, Jul 2009

Investors in this round

1 investor had bought by the notice of Aug 4, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander G. Rich · Executive Officer, Director
  • M.G. G. Sarngaharan · Executive Officer
  • Thomas A. Lynch · Executive Officer · 15.61% owner of the Issuer
  • Thomas G. Paese · Executive Officer
  • Tom K. Pease · Executive Officer
  • Brian K. Adamsky · Director
  • Frederick C. Tecce · Director
  • Jeffrey N. Meshulam · Director
  • Michael K. Greenebaum · Director
  • William K. Haseltine · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Seven tranche investment, with tranche date and investment amount as follows: 7/20/09 $5,041,206.00 3/23/10$1,000,000.80 9/9/10 $500,000.40 7/15/11 $249,999.60 1/22/13 $249,999.60 8/12/13 $500,000.404/8/14 $249,999.60 7/31/2014 250,000.40”

Signed by Jeffrey N. Meshulam, President and COO. Source: SEC Form D and 4 amendments, newest notice filed Aug 4, 2014. Read the notice at the SEC.

equitySEC
Jul 2009$7 MNo. 1$2 to $10 million

Profectus Biosciences Inc.: Raise no. 1, Jul 2009

Investors in this round

1 investor had bought by the notice of Feb 11, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey N. Meshulam · Executive Officer, Director
  • Alexander G. Rich · Director
  • Brian K. Adamsky · Director
  • Frederick C. Tecce · Director
  • M.G. G. Sarngadharan · Director
  • Michael J. Greenebaum · Director
  • Reinhard C. Kurth · Director
  • Thomas A. Lynch · Director
  • Thomas G. Paese · Director
  • William A. Haseltine · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Meshulam, President. Source: SEC Form D and 1 amendment, newest notice filed Feb 11, 2013. Read the notice at the SEC.

equity, debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Profectus Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2014).

    SEC Form D · Aug 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2014

That is all the official record says: Profectus Biosciences Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Profectus Biosciences Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Profectus Biosciences Inc.
NameRoleNamed in
Alexander G. RichExecutive officerAug 2014
M.G. G. SarngaharanExecutive officerAug 2014
Thomas A. Lynch15.61% owner of the IssuerAug 2014
Thomas G. PaeseExecutive officerAug 2014
Tom K. PeaseExecutive officerAug 2014
Jeffrey N. MeshulamExecutive officerApr 2014
Jeffrey MeshulamExecutive officerApr 2010
Jeffrey StelloExecutive officerJul 2009
Shawn Patrick O'BrienExecutive officerJul 2009
Alexander G. RichDirectorAug 2014
Brian K. AdamskyDirectorAug 2014
Frederick C. TecceDirectorAug 2014
Jeffrey N. MeshulamDirectorAug 2014
Michael K. GreenebaumDirectorAug 2014
William K. HaseltineDirectorAug 2014
M.G. G. SarngaharanDirectorApr 2014
Thomas A. LynchDirectorApr 2014
Thomas G. PaeseDirectorApr 2014
M.G. G. SarngadharanDirectorAug 2013
Reinhard A. KurthDirectorAug 2013
Thomas A LynchDirectorAug 2013
Michael J. GreenebaumDirectorFeb 2013
Reinhard C. KurthDirectorFeb 2013
William A. HaseltineDirectorFeb 2013
Stewart J. GreenebaumDirectorJul 2011
Brian AdamskyDirectorApr 2010
Joseph BerardinoDirectorApr 2010
Stewart G. GreenebaumDirectorApr 2010
Thomas G. LynchDirectorApr 2010
William A HaseltineDirectorApr 2010
Alexander RichDirectorJul 2009
Donald CaldwellDirectorJul 2009
M.G. SarngadharanDirectorJul 2009
Shawn Patrick O'BrienDirectorJul 2009
Stewart GreenebaumDirectorJul 2009
Thomas LynchDirectorJul 2009